First Eagle Investment Management LLC decreased its holdings in CareDx, Inc. (NASDAQ:CDNA - Free Report) by 58.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 493,582 shares of the company's stock after selling 703,412 shares during the quarter. First Eagle Investment Management LLC owned 0.94% of CareDx worth $32,083,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in CDNA. BlackRock Inc. purchased a new stake in CareDx during the 2nd quarter worth approximately $137,219,000. Bamco Inc. NY acquired a new stake in CareDx during the 2nd quarter worth approximately $55,214,000. Amova Asset Management Americas Inc. boosted its position in CareDx by 2.0% in the 1st quarter. Amova Asset Management Americas Inc. now owns 1,475,126 shares of the company's stock valued at $25,608,000 after buying an additional 28,510 shares during the period. Dimensional Fund Advisors LP boosted its position in CareDx by 11.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,461,914 shares of the company's stock valued at $25,375,000 after buying an additional 151,934 shares during the period. Finally, Renaissance Technologies LLC boosted its position in CareDx by 7.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,184,398 shares of the company's stock valued at $20,561,000 after buying an additional 79,200 shares during the period.
Wall Street Analyst Weigh In
Several equities analysts have commented on the stock. Canaccord Genuity Group set a $99.00 price target on shares of CareDx in a research note on Friday, October 30th. Wall Street Zen cut CareDx from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 31st. BTIG Research increased their price objective on CareDx from $81.00 to $92.00 and gave the company a "buy" rating in a research note on Friday, October 30th. Piper Sandler started coverage on CareDx in a report on Wednesday, November 11th. They issued an "overweight" rating and a $100.00 target price for the company. Finally, Weiss Ratings raised CareDx from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $70.33.
Read Our Latest Analysis on CDNA
CareDx Stock Performance
CDNA stock opened at $74.56 on Wednesday. The company's 50 day moving average price is $67.28 and its 200 day moving average price is $37.24. CareDx, Inc. has a fifty-two week low of $15.22 and a fifty-two week high of $90.87. The firm has a market capitalization of $3.92 billion, a price-to-earnings ratio of 111.70 and a beta of 2.51.
CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.45. CareDx had a net margin of 25.86% and a return on equity of 9.74%. The firm had revenue of $139.36 million for the quarter, compared to analysts' expectations of $121.96 million. During the same quarter last year, the company earned $0.03 earnings per share. The firm's revenue was up 39.3% compared to the same quarter last year. Equities analysts forecast that CareDx, Inc. will post 1.00 EPS for the current fiscal year.
Insider Buying and Selling
In other news, Director Michael Goldberg sold 13,800 shares of CareDx stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $79.15, for a total transaction of $1,092,270.00. Following the completion of the sale, the director directly owned 48,526 shares of the company's stock, valued at approximately $3,840,832.90. The trade was a 22.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Keith Kennedy sold 2,097 shares of CareDx stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $79.29, for a total transaction of $166,271.13. Following the sale, the chief financial officer directly owned 199,147 shares of the company's stock, valued at approximately $15,790,365.63. This trade represents a 1.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 77,858 shares of company stock worth $6,080,346. Insiders own 2.40% of the company's stock.
About CareDx
(
Free Report)
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
See Also
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc. (NASDAQ:CDNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.